UCB Capital Market Briefing Data Presentation of Bimekizumab Efficacy & Safety Versus Risankizumab In Patients With Active Psoriatic Arthritis: Results From A Head-to-head, Multicentre, Randomised, Phase 3b Study (BE BOLD)The briefing has taken place on Monday June 8th 2026 on the occasion of the results presentation from a head-to-head, multicentre, randomised, Phase 3b study (BE BOLD) at EULAR The videoconference webcast (including a Q&A session) was hosted by:Emmanuel Caeymaex : Executive Vice President, Head of Patient Evidence (UCB)Professor Iain McInnes: Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow Research and Contact DermatitisProfessor Joe Merola: President of the Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium, President of the Group for Research and Assessment of Psoriasis and Psoriatic ArthritisMaterials Please find the presentation herePlease find the webcast herePlease find the transcript hereFor any additional details or questions, do not hesitate to contact us at Investor-Relations@ucb.com.
